Explore the vast range of titles available.

These days, it's hard to escape the perception that the Aussie creative director is taking his coarse humour and beer-swilling ways into the refined and hallowed halls of some of the most cherished London and New York agencies. Expect to find more of us taking your jobs because we're willing, able and, I think, better equipped to take brands to market.

It is an axiom of military intelligence to ignore what the politicians are saying and to look at what the military is moving. What these movements reveal is that by the end of the third week in February, America and Britain will have their forces ready on Iraq's borders to fight a war to disarm Iraq and remove Saddam Hussein in the first two weeks of March. IAEA officials and intelligence sources admit it is extremely unlikely that Iraq has nuclear weapons squirrelled away. They admit too that evidence offered for Iraq's retention of them by the US and the UK n including an American claim that aluminium tubes for making gas centrifuges and evidence of rebuilding work at derelict plants n were wide of the mark. On Friday, the IAEA revealed that analysis of samples taken by UN nuclear inspectors in Iraq has showed no evidence of prohibited nuclear activity. Officials announced too that Iraq would be awarded egood grades' for its co-operation.

Herpes simplex virus (HSV) encephalitis is characterised by inflammation and swelling of the brain, resulting in death or severe neurocognitive sequelae. HSV encephalitis is treated with the antiviral aciclovir but still has substantial mortality and morbidity. Adjunct corticosteroids are sometimes used, but whether they improve the outcome is unclear. We aimed to establish the safety and efficacy of adjunct corticosteroids in HSV encephalitis. In this multicentre, observer-blind, randomised, phase 3 trial, adults with HSV encephalitis admitted to 53 hospitals in the UK were randomly assigned to receive intravenous dexamethasone (10 mg, four times daily for 4 days) plus intravenous aciclovir (10 mg/kg three times daily for at least 14 days; dexamethasone group), or intravenous aciclovir alone (control group). Eligible patients aged 16 years or older had suspected encephalitis (a febrile illness with new onset seizure, new focal neurological signs or alteration in consciousness, cognition, personality, or behaviour), with positive HSV type 1 or type 2 PCR test in CSF. Participants were randomly assigned by the trial team at the recruiting site, using a secure web-based randomisation programme. The primary outcome was verbal memory score at 26 weeks, measured by the Wechsler Memory Scale (WMS)-IV auditory memory index. Analyses of primary and secondary outcomes were performed according to the modified intention-to-treat principle, and safety analyses were based on whether participants received at least one dose of the study drug. Trial neuropsychologists assessing the primary outcome, and statisticians involved in the study's primary outcome, were masked to treatment group allocation. The trial is registered with the International Standard Randomised Controlled Trial Number Registry, ISRCTN11774734, and EudraCT, EudraCT2016-004835-19, and is completed. Between Sept 22, 2016, and Feb 2, 2022, 94 patients with HSV encephalitis were recruited, 47 (20 [43%] female and 27 [57%] male) to the dexamethasone group, and 47 (24 [51%] female and 23 [49%] male) to the control group. Dexamethasone was initiated a median 7 (IQR 4–8) days after hospital admission. Seven patients withdrew consent, and six were lost to follow-up. Thus, 81 were included in the modified intention-to-treat analysis (39 in the treatment group and 42 in the control group). The primary outcome, verbal memory score at 26 weeks, did not differ significantly between the groups (71 [SD 26] in the dexamethasone group, and 69 [SD 25] in the control group; adjusted difference 1·77 [95% CI –9·57 to 13·12; p=0·76). There were 27 adverse events involving 18 (38%) participants in the control group, and 25 adverse events involving 18 (40%) participants in the dexamethasone group. The most common serious adverse events were seizures requiring readmission to hospital (affecting one [2%] patient in the dexamethasone group and one [2%] patient in the control group) and thrombotic events, including deep vein thrombosis (affecting one [2%] patient in the dexamethasone group) and pulmonary embolism (affecting one [2%]patient in the dexamethasone group). There were no treatment-related deaths. In adults with HSV encephalitis, dexamethasone plus aciclovir had a satisfactory safety profile but did not improve verbal memory score compared with aciclovir alone. Given the established role of corticosteroids in other inflammatory encephalitides, our findings suggest that their early use in suspected encephalitis is unlikely to be harmful. Future studies should assess more targeted immunomodulatory approaches in HSV encephalitis. National Institute for Health and Care Research.

Despite [Wladislaw Szpilman]'s best efforts after the War the two men never met again and he was haunted until his death two years ago, aged 88, by the memory of the brave German who saved his life. THE relationship between Wladislaw Szpilman and [Wilm Hosenfeld] has been known to only a handful of people for the past 50 years. But now Hosenfeld's humanity is pivotal in director Roman Polanski's searing new film The Pianist, based on the musician's account of his five years in the Warsaw ghetto. He wrote: 'I want to comfort all these poor souls and ask for their forgiveness because the Germans have treated them so badly. We put an eternal curse on ourselves. I am ashamed to walk the streets.' SURVIVOR'S SONG: Adrien Brody, above, plays Wladislaw Szpilman in Polanski's film. Below right is the real Szpilman, pictured in 1946 HOSENFELD was taken prisoner by the Red Army on January 17, 1945, and his Russian interrogators were convinced he worked in intelligence. Made a scapegoat for the German brutality in Poland, he was tried as a war criminal, convicted by a Soviet court and sentenced to death, later commuted to life imprisonment with hard labour. He was appalled to discover that Hosenfeld was still a prisoner and contacted Szpilman in Warsaw for help. But in the confusion, and blocked by bureaucracy, Szpilman never got to see Hosenfeld before he died in 1952.